A trial of Roche’s successor to flu medicine Tamiflu has met its goal in a phase 3 trial, with results showing that the new drug Xofluza is well tolerated in children with the flu.
AstraZeneca’s Imfinzi cancer immunotherapy has hit the mark in a phase 3 trial in extensive-stage small cell lung cancer, setting up a potential rivalry with Roche’s PD-L1 class drug Tecent
